Navigation Links
Human Pheromone Sciences Announces Third Quarter Results

Increase in revenue with reduction in loss for the quarter

SAN JOSE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") today announced results for the third quarter and nine months ended September 30, 2008. For the three month period ending September 30, 2008, net revenues of $262,000 represented a 10% increase from the revenues of $239,000 in the prior year period, and resulted in a net loss of $30,000 ($.01 per share) as compared with a net loss of $93,000 ($.02 per share) for the same period of 2007. For the nine month period ending September 30, 2008, net revenues of $764,000 were 15% lower than the previous year's $902,000, resulting in a net loss of $181,000 ($0.04 per share) as compared with a net loss of $54,000 ($0.01 per share) in the first nine months of 2007. At September 30, 2008, the Company reflected a cash balance of $1,082,000 compared with $1,437,000 at December 31, 2007, a $355,000 reduction for the nine months of the current year as compared to a decline of $390,000 during the nine months ending September 30, 2007. There was no bank indebtedness at either date.

A spokesperson indicated "the Company was pleased that its cash utilization was only $355,000 for the first nine months of the year, and that net current liquidity (cash, accounts receivable and inventory, less current liabilities excluding current portion of deferred revenue) decreased only $433,000 for the same nine month period. This lower than expected asset utilization was a result of revenues generated under new licensing agreements, and a concerted effort to only invest in programs that are designed to generate additional future revenues."

"However, we still recognize that the marketing plans of our licensees can create unpredicted volatility of our quarterly performance, and this is not an acceptable posture for the Company in the long-term. We will still continue to nurture and expand our relationships with our licensees, and explore strategic ventures with other world-class marketing partners; we are also expanding our focus to include additional distribution channels for our current technology, as well as partners for the additional technologies we have developed."

Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction(R), REALM(R), innerREALM(R) and EROX(R) trademarks. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at

The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-KSB for the year ended December 31, 2007, and Form 10-Q for the quarter ended September 30, 2008, as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.

Tables follow


Condensed Balance Sheets

(Dollars in thousands)

September 30, December 31,

2008 2007



Cash and cash equivalents $ 1,082 $ 1,437

Accounts receivable 91 194

Inventories 50 25

Other current assets 34 40

Property and equipment, net 2 3

Total $1,259 $ 1,699

Liabilities and shareholders' equity

Accounts payable $31 $28

Other current liabilities 138 141

Deferred income - current 384 518

Deferred income - non-current 375 566

Common stock 21,029 20,963

Accumulated deficit (20,698) (20,517)

Total $1,259 $1,699


Condensed Statements of Operations


(Dollars in thousands, except per-share data)

Three months Nine months

ended ended

September 30, September 30,

2008 2007 2008 2007

Net revenue $262 $239 $764 $902

Cost of goods sold 86 94 240 277

Research and development 10 10 33 38

Selling, general and administrative 203 240 696 686

Income (loss) from operations (37) (105) (205) (99)

Other income 7 16 25 50

Provision for income taxes - 4 1 5

Net income (loss) $(30) $(93) $(181) $(54)

Income (loss) per share -

Basic and fully diluted $(0.01) $(0.02) $(0.04) $(0.01)

Weighted average common shares

outstanding -

Basic and fully diluted 4,152 4,152 4,152 4,152

Net income (loss) per share is based on the weighted average number of common shares and common equivalents outstanding during each period. Certain common stock equivalents are excluded when their effect would be anti-dilutive.

SOURCE Human Pheromone Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Transdermal Diclofenac enters Phase 1 Clinical Trial in Humans
2. Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics
3. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference
4. Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments
5. Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics
6. Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue
7. Complete Genomics Chooses Isilon IQ to Power Worlds First Complete Human Genome Sequencing Service
8. Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2008 Financial Results
9. Human Pheromone Sciences, Inc. - Shareholder Update
10. The human brain minimizes energy expenditure and integrates gravity in to the action plan
11. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model ... Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View ... years. Many AMA members have embraced this type of racing and several new model ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the environment are paramount. Insertion points for in-line sensors can represent a weak ... the InTrac 781/784 series of retractable sensor housings , which are designed ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. ... that Mr. Pierre Laurin , President and Chief Executive ... the upcoming Piper Jaffray 27 th Annual Healthcare Conference ... December 1-2, 2015. st , at 8.50am ... meetings throughout the day. The presentation will be available live ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
Breaking Biology News(10 mins):